
Cytek Biosciences, Inc.
- Jurisdiction
United States - LEI
549300K2J28BOC6FBO89 - ISIN
US23285D1090 (CTKB )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. Read full profile
Stock price
Fundamentals
- Net revenue
€168.89M - Gross margin
54.4% - EBIT
-€23.14M - EBIT margin
-13.7% - Net income
-€5.51M - Net margin
-3.3%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 8, 2024
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |